The compound you provided, 2-(3-chloro-N-(2-chloro-1-oxoethyl)anilino)-N-cyclohexyl-2-(3-pyridinyl)acetamide, is a complex organic molecule with a rather long and cumbersome name. It is likely a synthetically produced compound with a specific structure designed for a particular purpose.
**Here's why it's difficult to pinpoint its importance for research without further context:**
* **No Clear Identification:** The chemical name alone doesn't offer enough information. We need additional details like its:
* **Chemical formula:** To understand the exact arrangement of atoms.
* **Structure:** A diagram representing the arrangement of atoms and bonds.
* **Properties:** Its melting point, solubility, reactivity, etc.
* **Limited Information:** Without knowing its properties or intended use, it's hard to determine its research significance. Is it a potential drug candidate? A reagent for chemical synthesis? A tool for studying biological processes?
**To understand the research importance of this compound, you'll need more context. Here are some questions to consider:**
* **Where did you find this information?** A research paper, a chemical database, a patent?
* **What was the context?** Was it mentioned in relation to a specific disease or biological process?
* **What were the researchers studying?** What were the aims of the research?
Once you have more context, you can start to understand the significance of this compound.
**Remember:** It's crucial to be cautious when interpreting information about chemical compounds. Always rely on reputable sources and verified data.
ID Source | ID |
---|---|
PubMed CID | 4381127 |
CHEMBL ID | 1373969 |
CHEBI ID | 91820 |
Synonym |
---|
MLS000583953 , |
2-[(chloroacetyl)(3-chlorophenyl)amino]-n-cyclohexyl-2-pyridin-3-ylacetamide |
smr000206939 |
SR-01000709884-2 |
sr-01000709884 |
SR-01000709884-3 |
2-(3-chloro-n-(2-chloroacetyl)anilino)-n-cyclohexyl-2-pyridin-3-ylacetamide |
HMS2546P11 |
MLS003126533 |
cid_4381127 |
2-(3-chloro-n-(2-chloroacetyl)anilino)-n-cyclohexyl-2-(3-pyridyl)acetamide |
bdbm70761 |
2-[2-chloranylethanoyl-(3-chlorophenyl)amino]-n-cyclohexyl-2-pyridin-3-yl-ethanamide |
2-(3-chloro-n-(2-chloro-1-oxoethyl)anilino)-n-cyclohexyl-2-(3-pyridinyl)acetamide |
CHEMBL1373969 |
AKOS024440062 |
CHEBI:91820 |
Q27163616 |
Class | Description |
---|---|
organonitrogen compound | Any heteroorganic entity containing at least one carbon-nitrogen bond. |
organooxygen compound | An organochalcogen compound containing at least one carbon-oxygen bond. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 35.4813 | 0.0447 | 17.8581 | 100.0000 | AID485341 |
Nrf2 | Homo sapiens (human) | Potency | 12.5893 | 0.0920 | 8.2222 | 23.1093 | AID624171 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 6.7403 | 0.0184 | 6.8060 | 14.1254 | AID624172; AID624417 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 20.5962 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
TDP1 protein | Homo sapiens (human) | Potency | 2.0596 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 31.6228 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 3.9811 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
Smad3 | Homo sapiens (human) | Potency | 10.8813 | 0.0052 | 7.8098 | 29.0929 | AID588855; AID720534; AID720536; AID720537 |
67.9K protein | Vaccinia virus | Potency | 6.7833 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
P53 | Homo sapiens (human) | Potency | 19.9526 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
IDH1 | Homo sapiens (human) | Potency | 5.1735 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 3.1623 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 20.5962 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 89.1251 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 1.1220 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 18.8541 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 39.8107 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
geminin | Homo sapiens (human) | Potency | 8.5524 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 17.7828 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
lamin isoform A-delta10 | Homo sapiens (human) | Potency | 3.1623 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 0.3162 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
nuclear receptor coactivator 1 isoform 1 [Homo sapiens] | Homo sapiens (human) | IC50 (µMol) | 9.4870 | 1.1530 | 6.2803 | 9.9630 | AID602168; AID602235 |
glutathione S-transferase omega-1 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 0.0380 | 0.0220 | 0.0402 | 0.0670 | AID463081 |
transactivating tegument protein VP16 [Human herpesvirus 1] | Human alphaherpesvirus 1 (Herpes simplex virus type 1) | IC50 (µMol) | 5.3700 | 0.9460 | 4.7016 | 9.4870 | AID602167; AID602236 |
nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | IC50 (µMol) | 1.8040 | 0.1476 | 4.3309 | 9.9200 | AID602166; AID602234 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
recombinase A | Mycobacterium tuberculosis H37Rv | EC50 (µMol) | 3.1770 | 0.0180 | 23.2882 | 287.6000 | AID434968; AID435010 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Microphthalmia-associated transcription factor | Homo sapiens (human) | AC50 | 4.1620 | 0.0150 | 10.9049 | 46.0480 | AID493073; AID493102; AID493177 |
replicative DNA helicase | Mycobacterium tuberculosis H37Rv | AC50 | 3.1170 | 0.0570 | 30.7482 | 325.3000 | AID449749; AID449750 |
recombinase A | Mycobacterium tuberculosis H37Rv | IC90 (µMol) | 28.0000 | 2.8700 | 34.9100 | 100.0000 | AID489010 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
hormone activity | Glycoprotein hormones alpha chain | Homo sapiens (human) |
protein binding | Glycoprotein hormones alpha chain | Homo sapiens (human) |
follicle-stimulating hormone activity | Glycoprotein hormones alpha chain | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
extracellular region | Glycoprotein hormones alpha chain | Homo sapiens (human) |
extracellular space | Glycoprotein hormones alpha chain | Homo sapiens (human) |
Golgi lumen | Glycoprotein hormones alpha chain | Homo sapiens (human) |
follicle-stimulating hormone complex | Glycoprotein hormones alpha chain | Homo sapiens (human) |
pituitary gonadotropin complex | Glycoprotein hormones alpha chain | Homo sapiens (human) |
extracellular space | Glycoprotein hormones alpha chain | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |